The Benefit of Bermekimab in Patients With Systemic Sclerosis

The Benefit of Bermekimab in Patients With Systemic Sclerosis

Publication date: Aug 06, 2019

This is a proof-of concept RCT trying to generate evidence that inhibition of IL-1α through the administration of bermekimab may inhibit progression of SSc.

Concepts Keywords
Adalimumab Tumor
Aminotransferase Progressive organ dysfunction
Anorexia Hypersensitivity
Apocrine Glands Inflammation
Aspartate IGRA Chronic infection
Assay Total parenteral nutrition
Autoantibodies Contraception
Autocrine Major surgery
Bacterial Infection Medical specialties
Bilirubin Branches of biology
Blood Medicine
Cloned Autoimmune diseases
Collagen RTT
Colon Carcinoma Mucinoses
Contraception Connective tissue diseases
Cytosol Scleroderma
Defensin Systemic scleroderma
Digital Inflammation
Endothelium Platelet
European League Sjögren syndrome
Fatigue Ultrasound
Fibroblast Antibodies
Fibroblasts
Fibrosis
Gad
Gastrointestinal
Gastrointestinal Tract
Gender
Hematopoietic
HIV
Hypersensitivity
IL 1
IL 13
Immunodeficiency
Infection
Inflammation
Informed Consent
Interferon
Interleukin
Intravenously
Ischemia
Japanese
Lactation
Lean Body Mass
Lung
Lungs
Lymphocytes
Malabsorption
Metastatic
Microparticles
Monoclonal Antibodies
Monoclonal Antibody
Murine
Necrosis
Neutropenia
Nucleus
Organ
Pain
Pathogenesis
PHA
Placebo
Platelet
Pregnancy
Pregnancy Test
Primary Endpoint
Prime
Progressive
Pulmonary Hypertension
Randomized Clinical Trials
Receptor
Reflux
Rheumatic Disorder
Rheumatology
Salient
Scleroderma
Skin Depth
Skin Disorder
Solid Tumor
Staphylococcus Aureus
Syndrome
Systemic Sclerosis
Total Parenteral Nutrition
Transcription Factor
Transforming Growth Factor
Tuberculosis
Ultrasound
Vicious Cycle
Virus

Semantics

Type Source Name
disease MESH Systemic Sclerosis
disease DOID Systemic Sclerosis
gene UNIPROT RENBP
drug DRUGBANK Aspartame
disease MESH ACR
gene UNIPROT ACR
disease MESH Rheumatism
disease DOID mRSS
disease MESH Renal
disease MESH hypersensitivity
disease DOID hypersensitivity
disease MESH tuberculosis
disease DOID tuberculosis
pathway BSID Tuberculosis
disease MESH Latent tuberculosis
disease MESH infection
pathway BSID Primary immunodeficiency
disease MESH bacterial infection
disease MESH tumor
disease MESH hematologic malignancy
disease DOID hematologic malignancy
disease MESH Neutropenia
disease DOID Neutropenia
disease MESH Sepsis

Similar

Original Article

Leave a Comment

Your email address will not be published. Required fields are marked *